Advanced Basal Cell Carcinoma: What Dermatologists Need to Know About Current and Emerging Targeted Therapies

Format: Journal Supplement

Credit(s): 1.00 (60 min)

Release Date: May 13, 2022

Expiration Date: May 13, 2023

Credit Type(s):

Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)
Physicians/ABD MOC – ABD MOC Point(s)

PROGRAM OVERVIEW

While most basal cell carcinomas (BCCs) are amenable to surgery or radiotherapy, progression to locally advanced or metastatic BCC is life-threatening, difficult to treat, and not amenable to those standard options. Historically, few treatment options have been available for advanced BCC. The approval of the oral hedgehog pathway inhibitors vismodegib and sonidegib changed the treatment paradigm for patients with locally advanced and metastatic BCC. However, inadequate response or intolerance to these targeted therapies is frequent, leaving an unmet need for many patients with advanced BCC. To meet this need for additional treatment options, the anti-PD-1 therapy, cemiplimab, was recently approved for advanced BCC, and others, i.e. pembrolizumab and nivolumab, are currently in BCC clinical trials.

Advanced Basal Cell Carcinoma: What Dermatologists Need to Know About Current and Emerging Targeted Therapies will provide these clinicians with updates on treatment options, along with reinforcing the roles that dermatologists serve, e.g. monitoring and managing side effects of therapy and ensuring effective multidisciplinary management, in the care of patients with advanced BCC.